US Stock MarketDetailed Quotes

HURA TuHURA Biosciences

Watchlist

4.480
+0.480+12.00%

Close Dec 20 16:00 ET

4.280
-0.200-4.46%

Post 19:54 ET

189.43MMarket Cap-3.83P/E (TTM)

TuHURA Biosciences Stock Forum

JAYYFLASH

7 hours ago

$TuHURA Biosciences (HURA.US)$ Going to Be Very Bullish in 2025!!! " As 2024 comes to a close, we're reflecting on our achievements and looking ahead with excitement to the opportunities 2025 will bring."

Zenoph el Temlar

Dec 17 15:24

$TuHURA Biosciences (HURA.US)$
tik toc....

carlton griffiths

Dec 16 07:12

$TuHURA Biosciences (HURA.US)$ hoping some news will push a little

JAYYFLASH

Dec 15 11:27

$TuHURA Biosciences (HURA.US)$ Bullish . TUHURA Enters into Definitive Merger Agreement with $KANT to be Acquired 🔹Acquisition of KVA12123, a Phase 2-ready checkpoint inhibitor with demonstrated safety profile 🔹Expected to close Q1 '25

Youngbuffet

Dec 13 13:54

$TuHURA Biosciences (HURA.US)$ guys we just have to be patient next year this will move. not just happy with over 20m free float even after merger but with positive data this will move

Jaguar8

Dec 12 07:46

NEWS

$TuHURA Biosciences (HURA.US)$
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
Thursday, 12th December at 8:45 am
Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline
Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025
Cross product and technology synergies build on TuHURA's therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapy
Proposed Transactio...

JAYYFLASH

Dec 9 10:49

$TuHURA Biosciences (HURA.US)$ Bullish News From Tuhura " We are Developing Innate Immune Response Agonists and Bi-Specific Immune Modulating Antibody Drug Conjugates to Overcome Resistance to Cancer Immunotherapy."

JAYYFLASH

Dec 6 11:22

$TuHURA Biosciences (HURA.US)$ Bullish 🚀 “Half of patients with #MerkelCellCarcinoma have primary resistance and don’t respond to first-line treatments. It’s clear: new, more effective therapies are urgently needed.”